- Home
- VTVT vs CELU Comparison
VTVT vs CELU Comparison
Compare VTVT & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- CELU
- Stock Information
- Founded
- VTVT 2015
- CELU 2016
- Country
- VTVT United States
- CELU United States
- Employees
- VTVT N/A
- CELU N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- VTVT Health Care
- CELU Health Care
- Exchange
- VTVT Nasdaq
- CELU Nasdaq
- Market Cap
- VTVT 54.4M
- CELU 56.9M
- IPO Year
- VTVT 2015
- CELU N/A
- Fundamental
- Price
- VTVT $20.89
- CELU $1.97
- Analyst Decision
- VTVT Strong Buy
- CELU Strong Buy
- Analyst Count
- VTVT 2
- CELU 1
- Target Price
- VTVT $35.50
- CELU $6.00
- AVG Volume (30 Days)
- VTVT 4.2K
- CELU 167.1K
- Earning Date
- VTVT 11-12-2025
- CELU 12-05-2025
- Dividend Yield
- VTVT N/A
- CELU N/A
- EPS Growth
- VTVT N/A
- CELU N/A
- EPS
- VTVT N/A
- CELU N/A
- Revenue
- VTVT $17,000.00
- CELU $44,590,000.00
- Revenue This Year
- VTVT N/A
- CELU N/A
- Revenue Next Year
- VTVT N/A
- CELU $76.00
- P/E Ratio
- VTVT N/A
- CELU N/A
- Revenue Growth
- VTVT N/A
- CELU 4.45
- 52 Week Low
- VTVT $12.62
- CELU $1.00
- 52 Week High
- VTVT $26.99
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- VTVT 48.86
- CELU 41.25
- Support Level
- VTVT $20.19
- CELU $1.94
- Resistance Level
- VTVT $21.20
- CELU $2.06
- Average True Range (ATR)
- VTVT 0.97
- CELU 0.12
- MACD
- VTVT -0.30
- CELU 0.02
- Stochastic Oscillator
- VTVT 33.54
- CELU 9.31
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.